Perioperative and Oncological Outcome of Laparoscopic Resection of Gastrointestinal Stromal Tumour (GIST) of the Stomach

Background. Surgery remains the only curative treatment for gastrointestinal stromal tumour (GIST). Resection needs to ensure tumour-free margins while lymphadenectomy is not required. Thus, partial gastric resection is the treatment of choice for small gastric GISTs. Evidence on whether performing resection laparoscopically compromises outcome is limited. Methods. We compiled patients undergoing laparoscopic resection of suspected gastric GIST between 2003 and 2007. Follow-up was performed to obtain information on tumour recurrence. Results. Laparoscopic resection with free margins was performed in 21/22 patients. Histology confirmed GIST in 17 cases, 4 tumours were benign neoplasms. Median operation time and postoperative stay for GIST patients were 130 (range 80–201) mins and 7 (range 5–95) days. Two patients experienced stapler line leakage necessitating surgical revision. After median follow-up of 18 (range 1–53) months, no recurrence occurred. Conclusions. Laparoscopic resection of gastric GISTs yields good perioperative outcomes. Oncologic outcome needs to be assessed with longer follow-up. For posterior lesions, special precaution is needed. Laparoscopic resection could become standard for circumscribed gastric GISTs if necessary precautions for oncological procedures are observed

Endoscopic ultrasound in the pre-therapeutic staging of gastroesophageal adenocarcinoma: the diagnostic value in defining patients eligible for a neoadjuvant chemotherapy regimen

Introduction: Neoadjuvant chemotherapy regimens have been proven to decrease tumour size and stage and significantlyimprove progression-free and overall survival in the treatment of locoregional advanced gastroesophagealadenocarcinomas. Therefore, the pre-therapeutic staging of the tumour extension is of utmost importance for stratificationof patients into this individualized therapy regimen. Within the last years most experience has been gainedusing endoscopic ultrasound (EUS) and it has been considered as a valuable tool for the assessment of locoregionaldisease.Aim: To evaluate the accuracy of endoscopic ultrasound for the preoperative staging of locally advanced gastroesophagealadenocarcinomas with regard to defining patients’ eligibility for neoadjuvant chemotherapy.Material and methods: Between January 2006 and June 2007 consecutive patients (n = 47) who underwent resectionof a gastroesophageal adenocarcinoma and would have been potentially eligible for neoadjuvant chemotherapy wereincluded in this study. Preoperative EUS staging was compared to the postoperative histopathology results. Furthermore,the specificity, sensitivity and positive and negative predictive values for serosal invasion and/or lymph nodepositivity as an eligibility criterion for neoadjuvant chemotherapy were evaluated.Results: Thirty-seven patients were included in the analysis with adenocarcinomas of the distal oesophagus (n = 7),the oesophagogastric junction (n = 8) and the stomach (n = 22). The overall accuracy for predicting the T stage was64.9% (n = 24) with an over- and understaging of 13.5% (n = 5) and 21.6% (n = 8), respectively. The overall accuracyfor predicting the N stage was 64.7% (n = 22), with an over- and understaging of 26.5% (n = 9) and 8.8% (n = 3).Twenty-five out of 37 patients would have met the eligibility criteria for enrolment in a neoadjuvant chemotherapyregimen. The sensitivity was 76% (n = 19/25). The specificity was 75% (n = 9/12). The positive predictive value was86.4%. The negative predictive value was 60%.Conclusions: In this series the sensitivity and specificity of EUS for identification of patients eligible for neoadjuvantchemotherapy seem acceptable. Especially the positive predictive value, which expresses the probability that a patientidentified by EUS as eligible for neoadjuvant chemotherapy met the corresponding histopathological criteria, was high(86.4%). Therefore, it seems justified to apply neoadjuvant chemotherapy in patients identified as eligible by EUS. This underpins the importance of EUS in the staging of gastroesophageal carcinoma. In patients with a “negative” EUS result,the staging needs to be complemented by additional diagnostic modalities such as CT, PET or laparoscopy to facilitatethe correct identification of patients who meet the histopathological inclusion criteria for neoadjuvant chemotherapy

The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction-4

<p><b>Copyright information:</b></p><p>Taken from "The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction"</p><p>http://www.wjso.com/content/6/1/37</p><p>World Journal of Surgical Oncology 2008;6():37-37.</p><p>Published online 4 Apr 2008</p><p>PMCID:PMC2323006.</p><p></p

The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction-5

<p><b>Copyright information:</b></p><p>Taken from "The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction"</p><p>http://www.wjso.com/content/6/1/37</p><p>World Journal of Surgical Oncology 2008;6():37-37.</p><p>Published online 4 Apr 2008</p><p>PMCID:PMC2323006.</p><p></p

The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction-1

<p><b>Copyright information:</b></p><p>Taken from "The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction"</p><p>http://www.wjso.com/content/6/1/37</p><p>World Journal of Surgical Oncology 2008;6():37-37.</p><p>Published online 4 Apr 2008</p><p>PMCID:PMC2323006.</p><p></p

The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction-2

<p><b>Copyright information:</b></p><p>Taken from "The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction"</p><p>http://www.wjso.com/content/6/1/37</p><p>World Journal of Surgical Oncology 2008;6():37-37.</p><p>Published online 4 Apr 2008</p><p>PMCID:PMC2323006.</p><p></p